{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:28:03Z","timestamp":1788503283107,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023-3-016"],"award-info":[{"award-number":["2023-3-016"]}],"id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vitreous floaters are a common ocular condition that affects individuals of all ages. Although vitreous floaters are typically benign, they can significantly impair visual acuity and quality of life. Laser vitreolysis, which uses an Nd: YAG laser to vaporize collagenous vitreous opacities, is increasingly being used as a treatment option. However, there is currently a lack of evidence regarding its efficacy and the appropriate timing of its application. This study aims to evaluate the efficacy and safety of early intervention with YAG laser vitreolysis in treating symptomatic vitreous floaters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The present study is a randomized, controlled, double-blind clinical trial. A total of 70 participants with symptomatic floaters for 1\u00a0month were prospectively recruited. These participants will be randomly assigned to two groups, with 35 individuals in each group: the early treatment group and the delayed treatment group. Participants assigned to the early treatment group will undergo YAG laser vitreolysis immediately, followed by a sham laser treatment 3\u00a0months later. On the other hand, participants assigned to the delayed treatment group will receive a sham laser treatment and then undergo YAG laser vitreolysis 3\u00a0months later. The follow-up time points will be 1, 3, 6, and 12\u00a0months from randomization. Primary outcomes will be participants\u2019 self-reported improvement in visual disturbance on a scale of 1 to 10 and their scores on the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). Secondary outcomes will be an objective evaluation of the effectiveness of the treatment in reducing vitreous floaters through OCT and fundus photography and tracking any adverse events related to the eyes or overall health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This clinical trial aims to evaluate the effectiveness of YAG laser vitreolysis in treating symptomatic vitreous floaters and assess the safety of performing early intervention with YAG laser vitreolysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05800353\">NCT05800353<\/jats:ext-link>\n                      . Registered on 10 March 2023.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-024-07924-1","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T07:02:09Z","timestamp":1705129329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of early YAG laser vitreolysis for symptomatic vitreous floaters: the study protocol for a randomized clinical trial"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5364-0373","authenticated-orcid":false,"given":"Zhou","family":"Hangshuai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yanhua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Guangjin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Hongyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Fanlian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"issue":"1","key":"7924_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajo.2011.02.015","volume":"152","author":"J Sebag","year":"2011","unstructured":"Sebag J. Floaters and the quality of life. Am J Ophthalmol. 2011;152(1):3-4 e1.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"7924_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.survophthal.2015.11.008","volume":"61","author":"R Milston","year":"2016","unstructured":"Milston R, Madigan MC, Sebag J. Vitreous floaters: etiology, diagnostics, and management. Surv Ophthalmol. 2016;61(2):211\u201327.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"7924_CR3","first-page":"402","volume":"6","author":"BF Webb","year":"2013","unstructured":"Webb BF, Webb JR, Schroeder MC, North CS. Prevalence of vitreous floaters in a community sample of smartphone users. Int J Ophthalmol. 2013;6(3):402\u20135.","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"7924_CR4","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/IAE.0000000000000124","volume":"34","author":"CR Henry","year":"2014","unstructured":"Henry CR, Smiddy WE, Flynn HW Jr. Pars plana vitrectomy for vitreous floaters: is there such a thing as minimally invasive vitreoretinal surgery? Retina. 2014;34(6):1043\u20135.","journal-title":"Retina"},{"key":"7924_CR5","doi-asserted-by":"crossref","unstructured":"Garc\u00eda BG, Orduna Mag\u00e1n C, Alvarez-Peregrina C, Villa-Collar C, S\u00e1nchez-Tena M\u00c1. Nd:YAG laser vitreolysis and health-related quality of life in patients with symptomatic vitreous floaters. Eur J Ophthalmol. 2021:11206721211008036.","DOI":"10.1177\/11206721211008036"},{"issue":"1","key":"7924_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.eye.6700026","volume":"16","author":"YM Delaney","year":"2002","unstructured":"Delaney YM, Oyinloye A, Benjamin L. Nd:YAG vitreolysis and pars plana vitrectomy: surgical treatment for vitreous floaters. Eye (Lond). 2002;16(1):21\u20136.","journal-title":"Eye (Lond)"},{"issue":"9","key":"7924_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jamaophthalmol.2017.2388","volume":"135","author":"CP Shah","year":"2017","unstructured":"Shah CP, Heier JS. YAG laser vitreolysis vs sham YAG vitreolysis for symptomatic vitreous floaters: a randomized clinical trial. JAMA Ophthalmol. 2017;135(9):918\u201323.","journal-title":"JAMA Ophthalmol"},{"key":"7924_CR8","first-page":"0395","volume":"87","author":"GM Nunes","year":"2022","unstructured":"Nunes GM, Ludwig GD, Gemelli H, Zanotele M, Serracarbassa PD. Long-term evaluation of the efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous foaters. Arq Bras Oftalmol. 2022;87:0395.","journal-title":"Arq Bras Oftalmol"},{"issue":"5","key":"7924_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.survophthal.2020.02.007","volume":"65","author":"D Su","year":"2020","unstructured":"Su D, Shah CP, Hsu J. Laser vitreolysis for symptomatic floaters is not yet ready for widespread adoption. Surv Ophthalmol. 2020;65(5):589\u201391.","journal-title":"Surv Ophthalmol"},{"issue":"1","key":"7924_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ajo.2014.10.006","volume":"159","author":"LA Cowan","year":"2015","unstructured":"Cowan LA, Khine KT, Chopra V, Fazio DT, Francis BA. Refractory open-angle glaucoma after neodymium-yttrium-aluminum-garnet laser lysis of vitreous floaters. Am J Ophthalmol. 2015;159(1):138\u201343.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"7924_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/bjophthalmol-2016-309005","volume":"101","author":"EH Koo","year":"2017","unstructured":"Koo EH, Haddock LJ, Bhardwaj N, Fortun JA. Cataracts induced by neodymium-yttrium-aluminium-garnet laser lysis of vitreous floaters. Br J Ophthalmol. 2017;101(6):709\u201311.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"7924_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jamaophthalmol.2017.1683","volume":"135","author":"JI Lim","year":"2017","unstructured":"Lim JI. YAG laser vitreolysis-is it as clear as it seems? JAMA Ophthalmol. 2017;135(9):924\u20135.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"7924_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2020.10.026","volume":"128","author":"RA Shields","year":"2021","unstructured":"Shields RA, Cheng OT, Wolfe JD. Iatrogenic vitreous hemorrhage, subretinal hemorrhage, and branch retinal vein occlusion after YAG laser vitreolysis for symptomatic vitreous floaters. Ophthalmology. 2021;128(4):616.","journal-title":"Ophthalmology"},{"issue":"4","key":"7924_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s12325-020-01261-w","volume":"37","author":"A Katsanos","year":"2020","unstructured":"Katsanos A, Tsaldari N, Gorgoli K, Lalos F, Stefaniotou M, Asproudis I. Safety and efficacy of YAG laser vitreolysis for the treatment of vitreous floaters: an overview. Adv Ther. 2020;37(4):1319\u201327.","journal-title":"Adv Ther"},{"issue":"3","key":"7924_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1177\/1120672120968762","volume":"31","author":"GD Ludwig","year":"2021","unstructured":"Ludwig GD, Gemelli H, Nunes GM, Serracarbassa PD, Zanotele M. Efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous floaters: a randomized controlled trial. Eur J Ophthalmol. 2021;31(3):909\u201314.","journal-title":"Eur J Ophthalmol"},{"key":"7924_CR16","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hrobjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"1","key":"7924_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40123-021-00422-6","volume":"11","author":"T Lin","year":"2022","unstructured":"Lin T, Li T, Zhang X, Hui Y, Moutari S, Pazo EE, Dai G, Shen L. The efficacy and safety of YAG laser vitreolysis for symptomatic vitreous floaters of complete PVD or non-PVD. Ophthalmol Ther. 2022;11(1):201\u201314.","journal-title":"Ophthalmol Ther"},{"issue":"11","key":"7924_CR18","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2019.06.021","volume":"126","author":"JH Nguyen","year":"2019","unstructured":"Nguyen JH, Nguyen-Cuu J, Yu F, Yee KM, Mamou J, Silverman RH, Ketterling J, Sebag J. Assessment of vitreous structure and visual function after neodymium:yttrium-aluminum-Garnet laser vitreolysis. Ophthalmology. 2019;126(11):1517\u201326.","journal-title":"Ophthalmology"},{"issue":"6","key":"7924_CR19","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1097\/IAE.0000000000000065","volume":"34","author":"J Sebag","year":"2014","unstructured":"Sebag J, Yee KM, Wa CA, Huang LC, Sadun AA. Vitrectomy for floaters: prospective efficacy analyses and retrospective safety profile. Retina. 2014;34(6):1062\u20138.","journal-title":"Retina"},{"key":"7924_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ajoc.2016.08.005","volume":"4","author":"M Khoshnevis","year":"2016","unstructured":"Khoshnevis M, Nguyen-Cuu J, Sebag J. Floaters and reduced contrast sensitivity after successful pharmacologic vitreolysis with ocriplasmin. Am J Ophthalmol Case Rep. 2016;4:54\u20136.","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"6","key":"7924_CR21","first-page":"CD011676","volume":"6","author":"J Kokavec","year":"2017","unstructured":"Kokavec J, Wu Z, Sherwin JC, Ang AJ, Ang GS. Nd:YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters. Cochrane Database Syst Rev. 2017;6(6):CD011676.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"7924_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/ICU.0000000000000150","volume":"26","author":"DN Sommerville","year":"2015","unstructured":"Sommerville DN. Vitrectomy for vitreous floaters: analysis of the benefits and risks. Curr Opin Ophthalmol. 2015;26(3):173\u20136.","journal-title":"Curr Opin Ophthalmol"},{"issue":"9","key":"7924_CR23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.oret.2018.03.011","volume":"2","author":"J Sebag","year":"2018","unstructured":"Sebag J, Yee KMP, Nguyen JH, Nguyen-Cuu J. Long-term safety and efficacy of limited vitrectomy for vision degrading vitreopathy resulting from vitreous floaters. Ophthalmol Retina. 2018;2(9):881\u20137.","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"7924_CR24","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.ajo.2011.01.037","volume":"151","author":"CP Wilkinson","year":"2011","unstructured":"Wilkinson CP. Safety of vitrectomy for floaters\u2013how safe is safe? Am J Ophthalmol. 2011;151(6):919-920 e911.","journal-title":"Am J Ophthalmol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-07924-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-07924-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-07924-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T07:06:47Z","timestamp":1705129607000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-07924-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7924"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-07924-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3328066\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Institutional Ethical Committee of Dongyang People\u2019s Hospital and the reference number is Dongrenyi 2023-YX-424. Informed consent will be acquired from all study participants at the time of their recruitment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}